222 results about "Small interfering RNA" patented technology

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to ITGB1-siRNA lipid nanoparticles and application of the ITGB1-siRNA lipid nanoparticles in anti-angiogenesis treatment. Specifically, the ITGB1-siRNA lipid nanoparticles are successfully prepared, the lipid nanoparticles are loaded with integrin beta1 small interfering RNA (ITGB1-siRNA), are modified with triptolide (TP) and are coupled with anti-Flt1 peptide, so that the lipid nanoparticles can target vascular endothelial cells (VEC) and pericytes of CNV, and a good treatment effect on the CNV is achieved. Therefore, the lipid nanoparticles researched and developed by the invention are expected to become a new choice for treating the CNV-related eye diseases, and have good practical application value.

The present disclosure provides systems and methods for separating and characterizing oligonucleotides. Fixed dose combinations of small interfering RNAs can be subjected to denaturing ion pairing reverse phase liquid chromatography using optimal conditions to separate single RNA strands for purity analysis.

The invention provides a nucleic acid aptamer and a screening method thereof, the aptamer is of an oligonucleotide DNA structure, the nucleotide sequence of the nucleic acid aptamer is the nucleotide sequence of any DNA fragment as shown in SEQ ID NO: 1-9, and the nucleic acid aptamer can specifically target cardiac muscle cells (CMs). According to the invention, a new strategy can be provided for clinical treatment of cardiovascular diseases, and meanwhile, bioactive molecules such as microRNA (miRNA), small interfering RNA (small interfering RNA, siRNA), lipidosome, microspheres, microcapsules and the like can be carried to be used as an intracellular drug delivery tool.

The invention discloses a nano hydrogel preparation for packaging small interfering RNA (Ribonucleic Acid) and a preparation method, and belongs to the technical field of nano pesticides. Gold nanoparticles and dendritic mesoporous silica nanoparticles are used as composite carriers to load small interfering RNA, then a pectin solution is used for packaging, and the nano hydrogel preparation is prepared, so that the adhesion of a medicament is greatly enhanced, and rapid permeation and targeted delivery of the medicament are realized.

The disclosure relates to small interfering RNA (siRNA) molecules targeting MAPT and adeno-associated viral (AAV) particles encoding the same for treating tauopathies.

This disclosure relates to isolated oligonucleotides comprising duplex regions targeting human LPA mRNA, and delivery systems, kits and compositions comprising the same, and methods of using the same for inhibiting or downregulating Lp(a) gene expression.

The invention belongs to the technical field of biological medicines, and particularly relates to application of small interfering RNA (Ribonucleic Acid) of a targeted Zyx gene. The invention provides siRNA (small interfering Ribonucleic Acid) of a targeted Zyx gene, and further provides application of the siRNA in prevention and treatment of fibrosis interstitial lung diseases. Experimental data prove that in a mouse bleomycin model, siRNA of a targeted Zyx gene can effectively improve the survival rate of a sick mouse, alveolar wall thickening, lung substantive thickening and inflammatory cell infiltration of a Zyx knock-down group are not obvious, and pathological damage caused by bleomycin is effectively relieved through knock-down of the Zyx gene; collagen fiber deposition of a Zyx knock-down group is reduced, and the transcription level of fibrosis-related genes is obviously reduced.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as small interfering RNA (siRNA) molecules, able to inhibit proprotein convertase subtilisin kexin 9 (PCSK9) gene expression. Also disclosed are pharmaceutical compositions that include PCSK9 RNAi agents and methods of use thereof. The PCSK9 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the PCSK9 RNAi agents in vivo provides for in vivo provides for inhibition of PCSK9 gene expression and thereby reduction of PCSK9 protein. The RNAi agents can be used in methods of treatment of diseases or disorders mediated at least in part by PCSK9 gene expression, including among others hypercholesterolemia, familial hypercholesterolemia including heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH), familial hypobetalipoproteinemia, hyperlipidemia, coronary artery disease, polygenic dyslipidemia, heart disease, cardiovascular disease (CVD) including clinical atherosclerotic cardiovascular disease (ASCVD).

Provided herein, are compositions comprising GalNAc moieties that may be conjugated to an oligonucleotide. The oligonucleotide may be a small interfering RNA or an antisense oligonucleotide. Also provided herein are methods of treatment that include administering the composition to a subject.

Provided herein include methods, systems, and compositions for designing a sensor nucleic acid strand of a conditionally activatable small interfering RNA (siRNA) complex as well as the siRNA complexes generated using the method herein described and the component strands. The siRNA complex can be conditionally activated upon a complementary binding to an input nucleic acid strand (e.g. a mRNA of a biomarker gene specific to a target cell) through a sequence in a sensor nucleic acid strand of the nucleic acid complex. The activated nucleic acid complex can release a potent RNAi duplex formed by a core nucleic acid strand and a passenger nucleic acid strand, which can specifically inhibit a target RNA.

The present disclosure relates to the field of genetic engineering technology, and more specifically, to a targeting ligand. The targeting ligand provided herein forms a siRNA conjugate with a specific small interfering RNA sequence, which targets ANGPTL3 and degrades ANGPTL3 gene transcripts in cells, thereby reducing ANGPTL3 protein expression. Therefore, the siRNA conjugate formed with the targeting ligand provided herein can be used to prevent and / or treat dyslipidemia.

This disclosure relates to isolated oligonucleotides comprising duplex regions targeting human FXI mRNA, and delivery systems, kits and compositions comprising the same, and methods of using the same for inhibiting or downregulating FXI gene expression and treating or preventing a disease or disorder associated with aberrant or increased expression or activity of FXI or a disease or disorder where FXI plays a role.

The application provides a group of small interfering RNAs (siRNAs) targeting pyroptosis-related inflammatory reaction genes and application thereof. The pyroptosis-related inflammatory reaction genes include IL1A, IL1B, IL6, HMGB1, S100A8, S100A9 and BACH1. The application designs and synthesizes specific siRNA sequences for the above genes, and verifies that the siRNAs can efficiently and specifically inhibit the mRNA expression level of the corresponding genes through cell transfection and real-time fluorescent quantitative PCR. The application also provides a composition containing the siRNAs, a pharmaceutical composition and application thereof in the preparation of a drug for treating diseases mediated by pyroptosis-related inflammatory reaction genes (especially inflammatory diseases). The siRNAs and the composition thereof provide a new effective strategy for treating diseases related to excessive activation of pyroptosis-related inflammatory reactions, and have a wide application prospect.

The invention discloses siRNA capable of knocking down Pr18a9 gene expression and application of the siRNA, and relates to the technical field of biological medicine. The invention provides a positive-sense strand sequence and an antisense strand sequence of the siRNA, and the siRNA is used for preparing a preparation for promoting Schwann cell survival. According to the invention, the Prl8a9 gene of SCs is knocked down by virtue of a small interfering RNA technology; by improving the proliferation and migration capabilities of the Schwann cells, the apoptosis rate of the Schwann cells is reduced, and the survival rate of the Schwann cells is further improved. Meanwhile, a transcriptome sequencing technology is applied, key genes and pathways of Schwann cells treated by siPr18a9 are deeply excavated, and a theoretical support is provided for research on a repair mechanism after peripheral nerve injury.

The invention particularly relates to a glycosylated dendrimer for co-delivery of small interfering RNA (Ribonucleic Acid) and small molecular drugs as well as a preparation method and application of the glycosylated dendrimer. The nano platform provided by the invention is characterized in that an anti-inflammatory drug resveratrol (Res) and electrostatic adsorption small interfering RNA (si-Cp2e1) are loaded in a glycosylated dendrimer G5-Gal. The preparation method and the application comprise the following steps: preparation of G5-Gal, preparation of Res (at) G5-Gal, and preparation of Res (at) G5-Gal / si-Cp2e1. The preparation method is simple, the required raw materials are easy to obtain, the synthesis process is simple and convenient, separation and purification are easy, and the synthesized nano-drug has a liver targeting capability, can realize dual treatment of small molecule drug-small interfering RNA, and has a potential application prospect in the aspect of treatment of alcohol-related liver diseases.

The invention provides a long-chain non-coding RNA (Ribonucleic Acid) gene and application of small interfering RNA of the long-chain non-coding RNA gene in preparation of a medicine for inhibiting triple negative breast cancer. The nucleotide sequence of the long-chain non-coding RNA gene is as shown in SEQ ID NO. 1. The nucleotide sequence of the small interfering RNA is as shown in SEQ ID NO. 2. The invention also provides application of a reagent for detecting the long-chain non-coding RNA gene in preparation of a kit for diagnosing triple negative breast cancer. The invention also provides application of the long-chain non-coding RNA gene as a therapeutic target in screening of drugs for treating triple negative breast cancer. In-vitro and in-vivo experiments prove that proliferation, migration and invasion of triple negative breast cancer cells are promoted by over-expression of the long-chain non-coding RNA gene; in-vitro and in-vivo experiments prove that the proliferation, migration and invasion of triple negative breast cancer cells can be inhibited by knocking down the long-chain non-coding RNA gene.

Provided are compositions comprising an oligonucleotide that targets Angiopoietin-like 4 (ANGPTL4). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a metabolic or cardiovascular disorder by providing an oligonucleotide that targets ANGPTL4 to a subject in need thereof.

The present disclosure includes, among other things, compositions comprising cyclic peptides with selectivity for adipose tissues. The present disclosure includes, among other things, the recognition that the cyclic peptides with selectivity for adipose tissues can used in targeted delivery of a payload (e.g., an antisense oligonucleotide, or a small interfering RNA) to adipose tissues by conjugating such peptides to the payload. The present disclosure further includes, among other things, compositions comprising cyclic peptide conjugates and their use in the treatment of conditions of adipose tissues.

The invention discloses a bionic bimetallic polyphenol network nano-drug loaded with small non-coding RNA and a preparation method and application thereof, and belongs to the technical field of nano biomedicine.The nano-drug is loaded with small interference through a bimetallic polyphenol network, the surface of the nano-drug is coated with an M1 type macrophage membrane, and the safe and effective nano-drug is formed; the nano-drug acts on macrophages of an inflammation joint part, ROS is synergistically cleared by releasing tannic acid, Cu < 2 + > and small interfering RNA, TNF-alpha expression is inhibited, macrophage polarization is induced, meanwhile, Sr < 2 + > further plays a role in cartilage protection, and the purpose of treating osteoporosis and rheumatoid arthritis is achieved.

Disclosed herein are compositions comprising an oligonucleotide that targets GPAM. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with GPAM gene mutations that include providing an oligonucleotide that targets GPAM in a subject. Some examples of diseases that may be treated include liver diseases or cardiometabolic diseases.

Provided are compositions and methods of treating Coronavirus disease 2019 (COVID-19) in a subject, the method including administering to the subject a therapeutically effective amount of a composition comprising an exogenous nucleic acid and delivering the exogenous nucleic acid into a cell, wherein the exogenous nucleic acid comprises an antisense oligonucleotide, a small interfering RNA (siRNA), or locked nucleic acid, and wherein the exogenous nucleic acid binds to a target RNA and modulates gene expression of the target RNA, thereby treating Coronavirus disease 2019 (COVID-19) in the subject.

The invention provides application of protein arginine methyltransferase PRMT5 or a coding gene thereof as a target spot in preparation of a medicine for screening dialysis-related peritoneal fibrosis. The invention also provides application of an inhibitor of the protein arginine methyltransferase PRMT5 or the coding gene thereof in preparation of a medicine for treating dialysis-related peritoneal fibrosis. The invention also provides a siRNA (small interfering Ribonucleic Acid) of a specific target PRMT5 gene, and the nucleotide sequence of the siRNA is as follows: forward: 5 '-UAUAUCUCAGGUCCTT-3', and reverses: 5 '-GGACCUGAGAUGAUAUATT-3'). The invention also provides an application of the siRNA in preparation of a medicine for screening dialysis-related peritoneal fibrosis. Researches find that the expression level of PRMT5 in fibrotic peritoneal tissues of mice is up-regulated; and moreover, the expression of the PRMT5 is inhibited by virtue of the PRMT5 specific small interfering RNA and a specific inhibitor EPZ015666 of the PRMT5 specific small interfering RNA, so that dialysis-related peritoneal fibrosis can be obviously alleviated and relieved.

The application belongs to the technical field of gene diagnosis and treatment, and particularly relates to application of PIP4K2C gene in breast cancer detection, wherein the kit comprises a solid carrier and a detection reagent coated on the solid carrier, and the detection reagent is used for detecting PIP4K2C gene or PIP4K2C protein. The PIP4K2C gene and its protein expression product in the application can be used as a specific marker for diagnosing breast cancer. The small interfering RNA designed according to the PIP4K2C gene in the application can also be used as a gene therapy tool for treating breast cancer, thereby providing a new breast cancer treatment approach.

The application provides a culture medium for improving migration ability of mesenchymal stem cells, and belongs to the technical field of stem cells.The culture medium provided by the application is a migration-enhancing culture medium, which takes natural compound sinigrin as a core effective component and takes DMEM culture medium as an auxiliary culture medium.In addition, the application provides a new method for synergistically enhancing migration ability of mesenchymal stem cells by using a combination of sinigrin and small interfering RNA (siRNA) for lnc-XPNPEP1-1.The migration ability of cells can be synergistically enhanced by first transfecting mesenchymal stem cells with siRNA and then treating the mesenchymal stem cells with the migration-enhancing culture medium containing sinigrin, and the effect is significantly better than the effect of using the culture medium containing sinigrin alone.The scheme of the application can effectively improve the migration efficiency of mesenchymal stem cells, thereby improving the treatment potential of the mesenchymal stem cells in the field of tissue repair and regenerative medicine, and has important application prospect.

Disclosed herein is a composition comprising an oligonucleotide targeting MST1. The oligonucleotide may comprise a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein is a method for treating a condition associated with an MST1 mutant, comprising providing a subject with an oligonucleotide targeting MST1.

The invention provides application of lncPRPD regulation and control on GLRX5 in improving pork quality, the lncPRPD is lncRNA obtained by performing whole transcriptome sequencing analysis on longissimus dorsi muscle of Laiwu pigs, and the nucleotide sequence of the lncPRPD is as shown in SEQ ID NO: 1. The method comprises the following steps: firstly, synthesizing a small interfering RNA (Ribonucleic Acid) of the lncPRPD / GLRX5 and constructing a gene overexpression vector of the lncPRPD / GLRX5; then, detecting the combination of the lncPRPD and the GLRX5 protein by utilizing a Pulldown experiment and a Western blot experiment; the expression quantity of the GLRX5 is detected after interference and overexpression of the lncPRPD, and it is found that the lncPRPD can promote expression of the GLRX5 protein level; through detection experiments such as qPCR (quantitative polymerase chain reaction), Western blot, oil red O staining and the like, the lncPRPD and the GLRX5 are detected to be capable of promoting the differentiation of the pig precursor fat cells.

The present application relates to the application of long-chain non-coding RNA HILAR inhibitor in the preparation of drugs for preventing or / and treating lung adenocarcinoma metastasis. The present application provides specific intervention means for HILAR, and verifies the effectiveness of inhibiting lung adenocarcinoma metastasis: after the expression of HILAR is targeted and silenced in vitro by small interfering RNA technology, the invasion ability of lung adenocarcinoma cells is significantly inhibited, and the metastasis phenotype is obviously reversed; more importantly, through the delivery of short hairpin RNA by adeno-associated virus vector, the formation and development of lung metastasis are effectively reduced in a lung adenocarcinoma metastasis mouse model, and the in vivo imaging shows that the tumor luminescence signal intensity of the experimental group is continuously lower than that of the control group, and the overall survival condition of the animal is improved.

Provided are interfering RNAs such as small interfering RNAs (siRNAs) targeting the messengerRNA of adenine nucleotide translocator 2 (ANT2), pharmaceutical compositions comprising such, and therapeutic uses thereof for treating diseases associated with ANT2, for example,cancer and metabolic diseases.

The invention belongs to the technical field of pharmaceutical compositions, and relates to a small interfering RNA for treating cervical cancer and application thereof, the small interfering RNA comprises a first small interfering RNA and a second small interfering RNA, the first small interfering RNA is siE6 / E7, the siE6 / E7 is a nucleotide sequence as shown in a positive-sense strand of SEQ ID NO.7 and an antisense strand of SEQ ID NO.8, and the second small interfering RNA is a nucleotide sequence as shown in a positive-sense strand of SEQ ID NO.7 and an antisense strand of SEQ ID NO.8. The second small interfering RNA comprises a positive-sense strand and an antisense strand which is in reverse complementary pairing with the positive-sense strand, the positive-sense strand comprises nucleotide sequences as shown in SEQ ID NO.1, SEQ ID NO.3 and SEQ ID NO.5, and the antisense strand comprises nucleotide sequences as shown in SEQ ID NO.2, SEQ ID NO.4 and SEQ ID NO.6. The first small interfering RNA comprises a first small interfering RNA and a second small interfering RNA, and the second small interfering RNA comprises a positive-sense strand and an antisense strand which is in reverse complementary pairing with the positive-sense strand. The small interfering RNA designed by the invention can increase the anti-tumor activity of the human papilloma virus protein E6 / E7 small interfering RNA, and the anti-tumor activity of the E6 / E7 and CTBP co-knock-down treatment is obviously enhanced compared with the anti-tumor activity of the E6 / E7 and CTBP single knock-down treatment.

The invention discloses siRNA (small interfering ribonucleic acid) targeting SOX7, application of the siRNA in preparation of a medicine for treating chronic pain and the medicine, the small interfering RNA targeting the SOX7 gene comprises the SOX7 siRNA, the positive-sense strand sequence of the SOX7 siRNA is shown as SEQ.ID.NO.1, the antisense strand sequence of the SOX7 siRNA is shown as SEQ.ID.NO.2, and the small interfering RNA can target SOX7 genes of human and mice at the same time. The SOX7 siRNA is a group of siRNA for inhibiting the expression of the SOX7 gene, and siRNA targets are designed in a conserved region of the SOX7 gene and are located in a coding region. The expression of the SOX7 gene can be effectively reduced in vivo; by inhibiting the expression of the SOX7 gene, mechanical hyperalgesia generated by SNL induction can be effectively relieved, a foundation is laid for clinical treatment of sexual pain, and the application and popularization value is great.